According to the recent research report titled ‘GLOBAL Alzheimer’s Disease Therapeutics And Diagnostic Market 2019-2027’, available with Market Study Report, global Alzheimer’s disease therapeutics and diagnostics market is expected to record 7.78% CAGR over 2019-2027.
 

Industry experts cite that increasing research & development activities and booming elderly population are major factors fueling global Alzheimer’s disease therapeutics and diagnostics market growth. Growing cases of Alzheimer’s disease are also adding significant traction to the industry progression.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2515930/
 

Surging investment in research & development of personalized medicines and advancements in in-vitro diagnostic techniques are further contributing to the overall market outlook.
 

Despite the favorable business scenario, hefty cost of the treatment and strict government norms are negatively impacting worldwide Alzheimer’s disease therapeutics and diagnostics industry remuneration. Moreover, lack of skilled professionals and awareness regarding new therapies in the Alzheimer’s disease are negatively impacting the industry development.
 

Based on the regional landscape, Asia Pacific presently holds the largest market share, owing to increasing government investment in research & development for drugs and diagnostic test and growing population.
 

The prominent companies operating in global Alzheimer’s disease therapeutics and diagnostics market are Amarantus BioScience Holdings, Inc., Biogen Inc., Roche Diagnostics, Siemens Healthineers AG, ., Johnson & Johnson, Cognoptix Inc., DiaGenic ASA, GE Healthcare, Merck Group, AXON Neuroscience SE, Sun Pharmaceutical Industries Ltd., Piramal Enterprises Ltd, AbbVie Inc., and Baxter International.